779 related articles for article (PubMed ID: 27664325)
1. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
2. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
3. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
Khandelwal P; Lawrence J; Filipovich AH; Davies SM; Bleesing JJ; Jordan MB; Mehta P; Jodele S; Grimley MS; Kumar A; Myers K; Marsh RA
Pediatr Transplant; 2014 Feb; 18(1):94-102. PubMed ID: 24384050
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
[TBL] [Abstract][Full Text] [Related]
6. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation.
Yang J; Cheuk DK; Ha SY; Chiang AK; Lee TL; Ho MH; Chan GC
Pediatr Transplant; 2012 Nov; 16(7):771-8. PubMed ID: 22905718
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.
Resende CB; Rezende BM; Bernardes PT; Teixeira GM; Teixeira MM; Pinho V; Bittencourt H
Braz J Med Biol Res; 2017 Feb; 50(2):e5566. PubMed ID: 28198910
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients.
Khandelwal P; Teusink-Cross A; Davies SM; Nelson AS; Dandoy CE; El-Bietar J; Marsh RA; Kumar AR; Grimley MS; Jodele S; Myers KC
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1122-1127. PubMed ID: 28344057
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of basiliximab in the treatment of 87 cases of steroid-refractory or steroid-dependent acute graft-versus-host disease].
He ZX; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Chen X; Jiang EL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):120-127. PubMed ID: 35381672
[No Abstract] [Full Text] [Related]
12. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease.
Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Borjas-Almaguer OD; González-Llano O; Jaime-Pérez JC; Solano-Genesta M; Gómez-Guijosa M; Mancias-Guerra C; Tarin L; Gómez-Almaguer D
Haematologica; 2012 May; 97(5):717-22. PubMed ID: 22133770
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease.
Yalniz FF; Hefazi M; McCullough K; Litzow MR; Hogan WJ; Wolf R; Alkhateeb H; Kansagra A; Damlaj M; Patnaik MM
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1478-1484. PubMed ID: 28495641
[TBL] [Abstract][Full Text] [Related]
16. Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo.
Malagola M; Cancelli V; Skert C; Leali PF; Ferrari E; Tiburzi A; Sala ML; Donnini I; Chiusolo P; Mussetti A; Battista M; Turra A; Cattina F; Rambaldi B; Schieppati F; Polverelli N; Bernardi S; Perucca S; Marini M; Laszlo D; Savignano C; Patriarca F; Corradini P; Piccirillo N; Sica S; Bosi A; Russo D
Transplantation; 2016 Dec; 100(12):e147-e155. PubMed ID: 27861297
[TBL] [Abstract][Full Text] [Related]
17. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin.
McCaul KG; Nevill TJ; Barnett MJ; Toze CL; Currie CJ; Sutherland HJ; Conneally EA; Shepherd JD; Nantel SH; Hogge DE; Klingemann HG
J Hematother Stem Cell Res; 2000 Jun; 9(3):367-74. PubMed ID: 10894358
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
Martínez C; Solano C; Ferrá C; Sampol A; Valcárcel D; Pérez-Simón JA;
Biol Blood Marrow Transplant; 2009 May; 15(5):639-42. PubMed ID: 19361757
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation.
Inagaki J; Fukano R; Kodama Y; Nishimura M; Shimokawa M; Okamura J
Ann Hematol; 2014 Apr; 93(4):645-51. PubMed ID: 24146233
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation.
Inagaki J; Kodama Y; Fukano R; Noguchi M; Okamura J
Pediatr Transplant; 2015 Sep; 19(6):652-8. PubMed ID: 26103520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
